PharmaCyte Biotech Statistics Share Statistics PharmaCyte Biotech has 6.8M
shares outstanding. The number of shares has increased by -10.62%
in one year.
Shares Outstanding 6.8M Shares Change (YoY) -10.62% Shares Change (QoQ) 0% Owned by Institutions (%) 8.16% Shares Floating 6.09M Failed to Deliver (FTD) Shares 200 FTD / Avg. Volume 0.38%
Short Selling Information The latest short interest is 11.39K, so 0.17% of the outstanding
shares have been sold short.
Short Interest 11.39K Short % of Shares Out 0.17% Short % of Float 0.18% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is 0.3 and the forward
PE ratio is null.
PharmaCyte Biotech's PEG ratio is
0.
PE Ratio 0.3 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 0.18 P/FCF Ratio -3.05 PEG Ratio 0
Financial Ratio History Enterprise Valuation PharmaCyte Biotech has an Enterprise Value (EV) of -6.08M.
EV / Sales 0 EV / EBITDA -0.2 EV / EBIT 2.04 EV / FCF 2.04
Financial Position The company has a current ratio of 7.68,
with a Debt / Equity ratio of 0.
Current Ratio 7.68 Quick Ratio 7.68 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is 59.08% and Return on Invested Capital is -8378030.81%.
Return on Equity 59.08% Return on Assets 55.57% Return on Invested Capital -8378030.81% Revenue Per Employee n/a Profits Per Employee $15.33M Employee Count 2 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -26.62% in the
last 52 weeks. The beta is -0.24, so PharmaCyte Biotech's
price volatility has been lower than the market average.
Beta -0.24 52-Week Price Change -26.62% 50-Day Moving Average 1 200-Day Moving Average 1.32 Relative Strength Index (RSI) 65.98 Average Volume (20 Days) 52,619
Income Statement
Revenue n/a Gross Profit n/a Operating Income -4,377.9B Net Income 30.66M EBITDA 30.66M EBIT 30.66M Earnings Per Share (EPS) 3.19
Full Income Statement Balance Sheet The company has 15.17M in cash and 0 in
debt, giving a net cash position of 15.17M.
Cash & Cash Equivalents 15.17M Total Debt n/a Net Cash n/a Retained Earnings -84.97M Total Assets 55.17M Working Capital 19.46M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -2.98M
and capital expenditures -4, giving a free cash flow of -2.98M.
Operating Cash Flow -2.98M Capital Expenditures -4 Free Cash Flow -2.98M FCF Per Share -0.41
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields PMCB does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 337.28% FCF Yield -32.77%
Dividend Details Analyst Forecast Currently there are no analyst rating for PMCB.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number 25.81 Graham Upside 2184.07%
Stock Splits The last stock split was on Jul 12, 2021. It was a
backward
split with a ratio of 1:1550.
Last Split Date Jul 12, 2021 Split Type backward Split Ratio 1:1550
Scores Altman Z-Score -0.8 Piotroski F-Score 4
